News

SORT BY YEAR
17 February, 2021

ABG Acquisition Corp. I Announces Pricing of Upsized $131 Million Initial Public Offering

NEW YORK and HONG KONG, Feb. 16, 2021 /PRNewswire/ — ABG Acquisition Corp. I (the “Company”) today announced the pricing of its initial public offering of 13,100,000 Class A ordinary shares at a price of $10.00 per share. The shares will be listed on The Nasdaq Capital Market and trade under the ticker symbol “ABGI” […]

Read More
16 February, 2021

Ally Bridge Group Co-leads Mainstay Medical’s $108 Million Equity Financing

Funding to support U.S. commercial launch and global expansion February 16, 2021 08:00 AM Eastern Standard Time DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the closing of an equity financing in which it raised gross proceeds of US$108 million. Mainstay intends to use the funds to support the company’s commercial launch […]

Read More
8 February, 2021

Ally Bridge Portfolio News – Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III

Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “NAUT” Nautilus Biotechnology is expected to receive $350 million in proceeds through the business combination, including a $200 million fully committed PIPE […]

Read More
3 February, 2021

Syapse Announces $68 Million Strategic Investment with Ally Bridge Group and Northpond Ventures to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network

February 02, 2021 10:00 ET — Financing to support expanded partnering opportunities with life sciences, health systems, regulators and molecular labs — — Syapse committed to delivering real-world insights to improve outcomes for people with cancer — SAN FRANCISCO and NEW YORK and HONG KONG, Feb. 02, 2021 (GLOBE NEWSWIRE) — Syapse®, a leading real-world evidence company […]

Read More
18 December, 2020

Ally Bridge Portfolio News – Hua Medicine Successfully Completes Its Registration Phase III Trials. Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin’s Phase III Combination with Metformin Trial

Hua Medicine (the”Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: ● Successfully completes two Phase III 53-week registration trials in over 1,200+ Chinese patients in the midst of the COVID-19 global pandemic on time and with high quality data and results […]

Read More
7 December, 2020

Ally Bridge Portfolio News – Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies

Oral Arsenic Trioxide has Potential to Reduce Treatment Burden of Standard-of-Care Regimen that Cures Most Patients Dose Confirmation Study Expected to Begin in Second Half of 2021, Followed by Registration-Enabling Phase 3 Trial in 2022 $90.5 Million Strategic Financing Led by Bain Capital Life Sciences Extends Cash Runway through Multiple Expected Value Drivers into Second […]

Read More
19 November, 2020

MedAvail Completes $84 Million Private Placement Led by Ally Bridge Group

November 18, 2020 06:13 PM Eastern Standard Time MISSISSAUGA, Ontario & PHOENIX–(BUSINESS WIRE)–MedAvail Holdings, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its private placement offering as part of its business combination announced on November […]

Read More
18 November, 2020

Ally Bridge Portfolio News – MedAvail and MYOS RENS Technology Announce Closing of Business Combination

MedAvail, Inc. Set to Trade on NASDAQ Under Ticker Symbol “MDVL” MISSISSAUGA, Ontario & CEDAR KNOLLS, N.J.–(BUSINESS WIRE)–MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc. […]

Read More
31 October, 2020

Ally Bridge Portfolio News – Atea Pharmaceuticals Announces Pricing of Initial Public Offering

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a price […]

Read More
28 October, 2020

Ally Bridge Portfolio News – miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

Acquisition includes clinical stage anti-IGF–1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED). Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline BOULDER, Colo. and WALTHAM, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) —  miRagen Therapeutics, Inc. (“miRagen”) (NASDAQ: MGEN) today announced it has completed the […]

Read More